BACKGROUND: Intravenous Ig (IVIg), plasma exchange, and immunoadsorption are frequently used in the management of severe autoimmune diseases mediated by pathogenic IgG autoantibodies. These approaches modulating IgG levels can, however, be associated with some severe adverse reactions and a substantial burden to patients. Targeting the neonatal Fc receptor (FcRn) presents an innovative and potentially more effective, safer, and more convenient alternative for clearing pathogenic IgGs. METHODS: A randomized, double-blind, placebo-controlled first-in-human study was conducted in 62 healthy volunteers to explore single and multiple ascending intravenous doses of the FcRn antagonist efgartigimod. The study objectives were to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity. The findings of this study were compared with the pharmacodynamics profile elicited by efgartigimod in cynomolgus monkeys. RESULTS: Efgartigimod treatment resulted in a rapid and specific clearance of serum IgG levels in both cynomolgus monkeys and healthy volunteers. In humans, single administration of efgartigimod reduced IgG levels up to 50%, while multiple dosing further lowered IgGs on average by 75% of baseline levels. Approximately 8 weeks following the last administration, IgG levels returned to baseline. Efgartigimod did not alter the homeostasis of albumin or Igs other than IgG, and no serious adverse events related to efgartigimod infusion were observed. CONCLUSION: Antagonizing FcRn using efgartigimod is safe and results in a specific, profound, and sustained reduction of serum IgG levels. These results warrant further evaluation of this therapeutic approach in IgG-driven autoimmune diseases. TRIAL REGISTRATION: Clinicaltrials.gov NCT03457649. FUNDING: argenx BVBA.
RCT Entities:
BACKGROUND: Intravenous Ig (IVIg), plasma exchange, and immunoadsorption are frequently used in the management of severe autoimmune diseases mediated by pathogenic IgG autoantibodies. These approaches modulating IgG levels can, however, be associated with some severe adverse reactions and a substantial burden to patients. Targeting the neonatal Fc receptor (FcRn) presents an innovative and potentially more effective, safer, and more convenient alternative for clearing pathogenic IgGs. METHODS: A randomized, double-blind, placebo-controlled first-in-human study was conducted in 62 healthy volunteers to explore single and multiple ascending intravenous doses of the FcRn antagonist efgartigimod. The study objectives were to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity. The findings of this study were compared with the pharmacodynamics profile elicited by efgartigimod in cynomolgus monkeys. RESULTS:Efgartigimod treatment resulted in a rapid and specific clearance of serum IgG levels in both cynomolgus monkeys and healthy volunteers. In humans, single administration of efgartigimod reduced IgG levels up to 50%, while multiple dosing further lowered IgGs on average by 75% of baseline levels. Approximately 8 weeks following the last administration, IgG levels returned to baseline. Efgartigimod did not alter the homeostasis of albumin or Igs other than IgG, and no serious adverse events related to efgartigimod infusion were observed. CONCLUSION: Antagonizing FcRn using efgartigimod is safe and results in a specific, profound, and sustained reduction of serum IgG levels. These results warrant further evaluation of this therapeutic approach in IgG-driven autoimmune diseases. TRIAL REGISTRATION: Clinicaltrials.gov NCT03457649. FUNDING: argenx BVBA.
Authors: J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao Journal: Leukemia Date: 2012-05-03 Impact factor: 11.528
Authors: Derry C Roopenian; Gregory J Christianson; Thomas J Sproule; Aaron C Brown; Shreeram Akilesh; Nadja Jung; Stefka Petkova; Lia Avanessian; Eun Young Choi; Daniel J Shaffer; Peter A Eden; Clark L Anderson Journal: J Immunol Date: 2003-04-01 Impact factor: 5.422
Authors: James F Howard; Vera Bril; Ted M Burns; Renato Mantegazza; Malgorzata Bilinska; Andrzej Szczudlik; Said Beydoun; Francisco Javier Rodriguez De Rivera Garrido; Fredrik Piehl; Mariarosa Rottoli; Philip Van Damme; Tuan Vu; Amelia Evoli; Miriam Freimer; Tahseen Mozaffar; E Sally Ward; Torsten Dreier; Peter Ulrichts; Katrien Verschueren; Antonio Guglietta; Hans de Haard; Nicolas Leupin; Jan J G M Verschuuren Journal: Neurology Date: 2019-05-22 Impact factor: 9.910
Authors: E Sally Ward; Deborah Gelinas; Erwin Dreesen; Jolien Van Santbergen; Jan Terje Andersen; Nicholas J Silvestri; Joseph E Kiss; Darrell Sleep; Daniel J Rader; John J P Kastelein; Els Louagie; Gestur Vidarsson; Isabel Spriet Journal: Front Immunol Date: 2022-06-01 Impact factor: 8.786
Authors: Christopher Nelke; Marianna Spatola; Christina B Schroeter; Heinz Wiendl; Jan D Lünemann Journal: Neurotherapeutics Date: 2022-01-07 Impact factor: 6.088
Authors: Douglas B Cines; Sergei Zaitsev; Lubica Rauova; Ann H Rux; Victoria Stepanova; Sriram Krishnaswamy; Amrita Sarkar; M Anna Kowalska; Guohua Zhao; Alan E Mast; Laurence J Blumberg; Keith R McCrae; Mortimer Poncz; Jonathan J Hubbard; Michal Pyzik; Richard S Blumberg Journal: Blood Date: 2020-06-04 Impact factor: 22.113